Login Register Cart 0
Review Article

Inflammation as a Therapeutic Target for Various Deadly Disorders: A Review

Author(s): Ashwani K. Dhingra* and Bhawna Chopra

Volume 21, Issue 6, 2020

Page: [582 - 588] Pages: 7

DOI: 10.2174/1389450120666191204154115

Price: $65

Abstract

Inflammation is the multifaceted biological response of vascular tissues against injurious stimuli such as pathogens, irritants or infection. However, when inflammation goes away, it leads to produce quite serious life-threatening diseases like Alzheimer's, rheumatoid arthritis, heart attacks, colon cancer, etc. Therefore, inflammation suddenly has become one of the hottest areas of medical research. The present review article is aimed to provide a detailed outline of the fundamental causes and the surprising relationship of inflammation in the onset of sundry diseases or illnesses. Furthermore, the role of various anti-inflammatory drugs alone and in combination with other therapeutic drugs, in alleviating the life-threatening diseases has also been discussed.

Keywords: Inflammation, cancer, alzheimer, diabetes, auto-immune disorders, vascular tissues.

« Previous Next »
Graphical Abstract

[1]
Dhingra, A.K.; Chopra, B.; Dass, R.; Mittal, S.K. An update on Anti-inflammatory Compounds: A Review. Antiinflamm. Antiallergy Agents Med. Chem., 2015, 14(2), 81-97.
[http://dx.doi.org/10.2174/1871523014666150514102027] [PMID: 25973652]
[2]
Dinarello, C.A. Anti-inflammatory agents: present and future. Cell, 2010, 140(6), 935-950.
[http://dx.doi.org/10.1016/j.cell.2010.02.043] [PMID: 20303881]
[3]
Bowman, WC; Rand, D Textbook of pharmacology, 1980, 121-36.
[4]
Ashwani, K.; Dhingra, B.C.; Jagdeep, S.D.; Deo, N.P. Therapeutic potential of n-heterocyclic analogs as anti-inflammatory agents. Antiinflamm. Antiallergy Agents Med. Chem., 2017, 16, 1-17.
[5]
Mario, D Chiara di L, Mihaela B, Enrico S, Lorena D, Enrica B, et al. Plant food supplements with anti-inflammatory properties: a systematic review (I). Crit. Rev. Food Sci. Nutr., 2013, 53, 403-413.
[http://dx.doi.org/10.1080/10408398.2012.682123]
[6]
Ridker, P.M.; Manson, J.E.; Buring, J.E.; Muller, J.E.; Hennekens, C.H. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation, 1990, 82(3), 897-902.
[http://dx.doi.org/10.1161/01.CIR.82.3.897] [PMID: 2203556]
[7]
Ridker, P.M. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J. Thromb. Haemost., 2009, 7(Suppl. 1), 332-339.
[http://dx.doi.org/10.1111/j.1538-7836.2009.03404.x] [PMID: 19630828]
[8]
Ridker, P.M.; Danielson, E.; Fonseca, F.A. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med., 2008, 359(21), 2195-2207.
[http://dx.doi.org/10.1056/NEJMoa0807646] [PMID: 18997196]
[9]
Ridker, P.M. Inflammation, high-sensitivity C-reactive protein, and vascular protection. Tex. Heart Inst. J., 2010, 37(1), 40-41.
[PMID: 20200625]
[10]
Goldfine, A.B.; Fonseca, V.; Jablonski, K.A. Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann. Intern. Med., 2013, 159(1), 1-12.
[http://dx.doi.org/10.7326/0003-4819-159-1-201307020-00003] [PMID: 23817699]
[11]
Herrero, L.; Shapiro, H.; Nayer, A.; Lee, J.; Shoelson, S.E. Inflammation and adipose tissue macrophages in lipodystrophic mice. Proc. Natl. Acad. Sci. USA, 2010, 107(1), 240-245.
[http://dx.doi.org/10.1073/pnas.0905310107] [PMID: 20007767]
[12]
Goldfine, A.B.; Fonseca, V.; Shoelson, S.E. Therapeutic approaches to target inflammation in type 2 diabetes. Clin. Chem., 2011, 57(2), 162-167.
[http://dx.doi.org/10.1373/clinchem.2010.148833] [PMID: 21098138]
[13]
Goldfine, A.B.; Shoelson, S.E. Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J. Clin. Invest., 2017, 127(1), 83-93.
[http://dx.doi.org/10.1172/JCI88884] [PMID: 28045401]
[14]
Romeo, G.R.; Lee, J.; Shoelson, S.E. Metabolic syndrome, insulin resistance, and roles of inflammation--mechanisms and therapeutic targets. Arterioscler. Thromb. Vasc. Biol., 2012, 32(8), 1771-1776.
[http://dx.doi.org/10.1161/ATVBAHA.111.241869] [PMID: 22815343]
[15]
Eberhart, C.E.; Coffey, R.J.; Radhika, A.; Giardiello, F.M.; Ferrenbach, S.; DuBois, R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 1994, 107(4), 1183-1188.
[http://dx.doi.org/10.1016/0016-5085(94)90246-1] [PMID: 7926468]
[16]
Kargman, S.L.; O’Neill, G.P.; Vickers, P.J.; Evans, J.F.; Mancini, J.A.; Jothy, S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res., 1995, 55(12), 2556-2559.
[PMID: 7780968]
[17]
Kutchera, W.; Jones, D.A.; Matsunami, N. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc. Natl. Acad. Sci. USA, 1996, 93(10), 4816-4820.
[http://dx.doi.org/10.1073/pnas.93.10.4816] [PMID: 8643486]
[18]
Gustafson-Svärd, C.; Lilja, I.; Hallböök, O.; Sjödahl, R. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gut, 1996, 38(1), 79-84.
[http://dx.doi.org/10.1136/gut.38.1.79] [PMID: 8566864]
[19]
DuBois, R.N.; Radhika, A.; Reddy, B.S.; Entingh, A.J. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology, 1996, 110(4), 1259-1262.
[http://dx.doi.org/10.1053/gast.1996.v110.pm8613017] [PMID: 8613017]
[20]
Williams, C.S.; Luongo, C.; Radhika, A. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology, 1996, 111(4), 1134-1140.
[http://dx.doi.org/10.1016/S0016-5085(96)70083-5] [PMID: 8831610]
[21]
Shattuck-Brandt, R.L.; Varilek, G.W.; Radhika, A.; Yang, F.; Washington, M.K.; DuBois, R.N. Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology, 2000, 118(2), 337-345.
[http://dx.doi.org/10.1016/S0016-5085(00)70216-2] [PMID: 10648462]
[22]
Bamba, H.; Ota, S.; Kato, A.; Adachi, A.; Itoyama, S.; Matsuzaki, F. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int. J. Cancer, 1999, 83(4), 470-475.
[http://dx.doi.org/10.1002/(SICI)1097-0215(19991112)83:4<470:AID-IJC6>3.0.CO;2-F] [PMID: 10508481]
[23]
Tsujii, M.; DuBois, R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 1995, 83(3), 493-501.
[http://dx.doi.org/10.1016/0092-8674(95)90127-2] [PMID: 8521479]
[24]
DuBois, R.N.; Shao, J.; Tsujii, M.; Sheng, H.; Beauchamp, R.D. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res., 1996, 56(4), 733-737.
[PMID: 8631005]
[25]
Qiao, L.; Kozoni, V.; Tsioulias, G.J. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim. Biophys. Acta, 1995, 1258(2), 215-223.
[http://dx.doi.org/10.1016/0005-2760(95)00100-Q] [PMID: 7548186]
[26]
Thun, M.J.; Namboodiri, M.M.; Calle, E.E.; Flanders, W.D.; Heath, C.W., Jr Aspirin use and risk of fatal cancer. Cancer Res., 1993, 53(6), 1322-1327.
[PMID: 8443812]
[27]
Giovannucci, E.; Egan, K.M.; Hunter, D.J. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med., 1995, 333(10), 609-614.
[http://dx.doi.org/10.1056/NEJM199509073331001] [PMID: 7637720]
[28]
Schreinemachers, D.M.; Everson, R.B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology, 1994, 5(2), 138-146.
[http://dx.doi.org/10.1097/00001648-199403000-00003] [PMID: 8172988]
[29]
Thun, M.J.; Henley, S.J.; Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst., 2002, 94(4), 252-266.
[http://dx.doi.org/10.1093/jnci/94.4.252] [PMID: 11854387]
[30]
Bazan, N.G.; Colangelo, V.; Lukiw, W.J. Prostaglandins and other lipid mediators in Alzheimer’s disease. Prostaglandins Other Lipid Mediat., 2002, 68-69, 197-210.
[http://dx.doi.org/10.1016/S0090-6980(02)00031-X] [PMID: 12432919]
[31]
Subbaramaiah, K.; Telang, N.; Ramonetti, J.T. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res., 1996, 56(19), 4424-4429.
[PMID: 8813136]
[32]
Chan, G.; Boyle, J.O.; Yang, E.K. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res., 1999, 59(5), 991-994.
[PMID: 10070952]
[33]
Tucker, O.N.; Dannenberg, A.J.; Yang, E.K. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res., 1999, 59(5), 987-990.
[PMID: 10070951]
[34]
Ristimäki, A.; Honkanen, N.; Jänkälä, H.; Sipponen, P.; Härkönen, M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res., 1997, 57(7), 1276-1280.
[PMID: 9102213]
[35]
Koki, A.T.; Khan, N.K.; Woerner, B.M. Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers. Prostaglandins Leukot. Essent. Fatty Acids, 2002, 66(1), 13-18.
[http://dx.doi.org/10.1054/plef.2001.0335] [PMID: 12051953]
[36]
Milas, L.; Kishi, K.; Hunter, N.; Mason, K.; Masferrer, J.L.; Tofilon, P.J. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl. Cancer Inst., 1999, 91(17), 1501-1504.
[http://dx.doi.org/10.1093/jnci/91.17.1501] [PMID: 10469752]
[37]
Trifan, O.C.; Durham, W.F.; Salazar, V.S. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res., 2002, 62(20), 5778-5784.
[PMID: 12384538]
[38]
Berchtold, N.C.; Cotman, C.W. Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s. Neurobiol. Aging, 1998, 19(3), 173-189.
[http://dx.doi.org/10.1016/S0197-4580(98)00052-9] [PMID: 9661992]
[39]
Brookmeyer, R.; Gray, S.; Kawas, C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health, 1998, 88(9), 1337-1342.
[http://dx.doi.org/10.2105/AJPH.88.9.1337] [PMID: 9736873]
[40]
Tiraboschi, P.; Hansen, L.A.; Thal, L.J.; Corey-Bloom, J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology, 2004, 62(11), 1984-1989.
[http://dx.doi.org/10.1212/01.WNL.0000129697.01779.0A] [PMID: 15184601]
[41]
Szekely, C.A.; Town, T.; Zandi, P.P. NSAIDs for the chemoprevention of Alzheimer’s disease. Subcell. Biochem., 2007, 42, 229-248.
[http://dx.doi.org/10.1007/1-4020-5688-5_11] [PMID: 17612054]
[42]
Cochran, F.R.; Vitek, M.P. Neuroinflammatory mechanisms in Alzheimer’s disease: new opportunities for drug discovery. Expert Opin. Investig. Drugs, 1996, 5, 449-455.
[http://dx.doi.org/10.1517/13543784.5.4.449]
[43]
Breitner, J.C.S. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer’s disease. Annu. Rev. Med., 1996, 47, 401-411.
[http://dx.doi.org/10.1146/annurev.med.47.1.401] [PMID: 8712791]
[44]
McGeer, P.L.; McGeer, E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev., 1995, 21(2), 195-218.
[http://dx.doi.org/10.1016/0165-0173(95)00011-9] [PMID: 8866675]
[45]
Stewart, W.F.; Kawas, C.; Corrada, M.; Metter, E.J. Risk of Alzheimer’s disease and duration of NSAID use. Neurology, 1997, 48(3), 626-632.
[http://dx.doi.org/10.1212/WNL.48.3.626] [PMID: 9065537]
[46]
Hampel, H.; Muller, N. Inflammatory and immunological mechanisms in Alzheimer’s disease. Drug News Perspect., 1995, 8, 599-608.
[47]
Bauer, M.K.A.; Lieb, K.; Schulze-Osthoff, K. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur. J. Biochem., 1997, 243(3), 726-731.
[http://dx.doi.org/10.1111/j.1432-1033.1997.00726.x] [PMID: 9057838]
[48]
Chang, J.W.; Coleman, P.D.; O’Banion, M.K. Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA expression is decreased in Alzheimer’s disease. Neurobiol. Aging, 1996, 17(5), 801-808.
[http://dx.doi.org/10.1016/0197-4580(96)00110-8] [PMID: 8892355]
[49]
Rogers, J.; Kirby, L.C.; Hempelman, S.R. Clinical trial of indomethacin in Alzheimer’s disease. Neurology, 1993, 43(8), 1609-1611.
[http://dx.doi.org/10.1212/WNL.43.8.1609] [PMID: 8351023]
[50]
Kurabi, A.; Pak, K.; Ryan, A.F.; Wasserman, S.I. Innate Immunity: Orchestrating Inflammation and Resolution of Otitis Media. Curr. Allergy Asthma Rep., 2016, 16(1), 6.
[51]
Li, X.; Hawkins, G.A.; Ampleford, E.J. Genome-wide association study identifies TH1 pathway genes associated with lung function in asthmatic patients. J. Allergy Clin. Immunol., 2013, 132(2), 313-320.
[52]
Coussens, L.M.; Werb, Z. 2002 Dec; Inflammation and cancer. Nature, 19420(6917), 860-867.
[http://dx.doi.org/10.1038/nature01322]
[53]
Hashemi, G.N.; Najafi, M.; Salehi, E.; Farhood, B.; Mortezaee, K. Cyclooxygenase-2 in cancer: A review. J. Cell. Physiol., 2019, 234(5), 5683-5699.
[http://dx.doi.org/10.1002/jcp.27411]
[54]
Sotirios, T; Alexios, SA; Evangelos, O O, et al. The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. ECR 2019; 14(1),

Rights & Permissions Print Cite
Article Metrics
30
© 2024 Bentham Science Publishers | Privacy Policy